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Abstract
An important feature of autoimmune diseases is the overlap of
pathophysiological characteristics. Clustering of autoimmune
diseases in families suggests that genetic variants may
contribute to autoimmunity. The aim of the present study was to
investigate the role of the interferon induced with helicase
domain 1 (IFIH1) A946T (rs1990760 A>G) variant in
rheumatoid arthritis (RA), as this was recently associated with
susceptibility to type 1 diabetes. A total of 965 Caucasians with
RA and 988 healthy controls were genotyped for IFIH1 A946T.
Gene expression of IFIH1 was measured in peripheral blood
leukocytes using real-time PCR. Genotypes were equally
distributed in both RA cases and healthy controls (odds ratio for
allele C = 0.9, 95% confidence interval = 0.8–1.0, P = 0.3). No
association was detected after stratification by sex, age at onset,
rheumatoid factor status, anti-cyclic citrullinated peptide status
or radiological joint damage. Levels of IFIH1 mRNA were
approximately twofold higher in blood leucocytes of RA cases
compared with healthy controls (P < 0.0001). These results
indicate that the IFIH1 is upregulated in RA but that the A946T
variant does not contribute significantly to the genetic
background of RA.
Introduction
Autoimmune diseases are characterised by a loss of immuno-
logical tolerance and by chronic inflammation that frequently
results in tissue damage. Collectively the diseases affect
about 4–5% of the population and have a multifactorial origin
involving both genetic and environmental factors [1]. An impor-
tant feature of autoimmune diseases is the overlap of common
pathophysiological characteristics as well as their co-occur-
rence in families, as indicated by studies documenting the
increased prevalence of rheumatoid arthritis (RA) and other
autoimmune diseases including type 1 diabetes (T1D) [2,3].
Such findings suggest the presence of common genetic vari-
ants predisposing to autoimmunity.
The region most commonly associated with susceptibility to
autoimmune diseases is the human leukocyte antigen class II
genes on chromosome 6p21.3 [4-6]. Approximately one-third
of the genetically encoded risk of developing RA arises from
DRB1 alleles, although recent evidence suggested that this
association is primarily with production of anti-cyclic citrulli-
nated peptide (anti-CCP) antibodies [7]. The identification of
disease-related genes outside the major histocompatibility
complex has been much more difficult; however, recent suc-
cesses have included the identification of cytotoxic-T-lym-
phocyte-associated 4 with Graves disease and T1D [8,9],
and, more recently, the association of PTPN22 with several
diseases including T1D [10], Graves disease [11], RA [12]
and systemic lupus erythematosus [13].
The interferon induced with helicase C domain 1 (IFIH1) gene,
also referred to as mda-5 or Helicard, is located at 2q24.3 and
encodes an early type 1 IFN response gene. It is a helicase
that detects dsRNA, resulting in the activation of transcription
factors such as IFN-regulatory factor 3 and NF-κB. IFIH1 is
CCP = cyclic citrullinated peptide; IFIH1 = interferon induced with helicase domain 1; IFN = interferon; NF = nuclear factor; PCR = polymerase chain 
reaction; RA = rheumatoid arthritis; RF = rheumatoid factor; SNP = single nucleotide polymorphism; T1D = type 1 diabetes.Arthritis Research & Therapy    Vol 9 No 2    Marinou et al.
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expressed at low levels in most tissues, with relatively higher
expression in immune cells. A recent study reported convinc-
ing statistical evidence for IFIH1 being the sixth identified T1D
susceptibility locus with association of a nonsynonomous sin-
gle nucleotide polymorphism, A946T (rs1990760 A>G) [14].
The A946T SNP leads to an alanine for threonine substitution
at position 946 and the C allele was found to be a risk factor
for T1D. To determine whether this variant is involved in the
genetic background of RA, we compared genotypes in a large
case–control study and also in relation to clinical features
including rheumatoid factors (RFs) and anti-CCP status and
radiological joint damage. We examined levels of IFIH1 mRNA
in peripheral blood leukocytes of patients and controls.
Materials and methods
Study populations
A total of 965 white Caucasian individuals with RA and of 988
healthy unrelated individuals participated in this study. The
control group was from the Sheffield area and each individual
was 18 years of age or older with no history of an inflammatory
joint disorder. The South Sheffield Research Ethics Commit-
tee approved this study and informed consent was obtained
from all participants. RA was diagnosed according to the
American College of Rheumatology diagnostic criteria. The
measurements of RFs, anti-CCP and modified Larsen scores
were obtained as previously described [7].
Single nucleotide polymorphism genotyping
Blood samples were collected in ethylenediamine tetraacetic
acid-anticoagulated tubes and DNA was extracted using
standard methods. A Taqman SNP genotyping assay was
designed for rs1990760 by Applied Biosystems (PE Biosys-
tems, Foster City, CA, USA). The sequences of the primers
were, 5'-ACCATTTATTTGATAGTCGGCACACT-3' (forward)
and 5'-CCCTTTGATACTTATAGGGAACTTTACATTGT-3'
(reverse). The sequences of the allele-specific probes were 5'-
TTTTGCAGTGCTTTGTT-3' for the C allele (reporter dye VIC)
and 5'-CTTTTGCAGTGTTTTGTT-3' for the T allele (reporter
dye FAM.
Thermal cycling was performed as follows; after an initial dena-
turation and enzyme activation of 10 minutes at 95°C, samples
were subjected to 40 cycles of 15 seconds at 95°C for dena-
turation and 60 seconds at 60°C for annealing/extension. To
ensure the accuracy of genotyping results we included multi-
ple positive and negative controls in all genotyping plates, and
we repeated 10% of our samples to eliminate genotyping
errors. Thermal cycling in 384-well plates was performed on
the PTC-225 DNA engine Tetrad (MJ Research, San Fran-
cisco, CA, USA) and genotypes were determined using an
ABI Prism 7900 HT (PE Biosystems). Genotyping was con-
firmed by DNA sequencing of the six A946T individuals, com-
prising two of each genotype.
mRNA quantitation
Whole blood was collected into Qiagen PAXgene tubes and
total RNA was extracted according to the PAXgene RNA sys-
tem (Qiagen, Crawley, UK). The synthesis of cDNA and the
gene expression analysis were performed in 200 RA cases
and in 200 healthy controls as described previously [15]. The
sequences of the primers were 5'-CAGTGTGCTAGCCT-
GTTC-3' (sense) and 5'-TCCTTGAATTCTGGGGTC-3' (anti-
sense). The levels of IFIH1 mRNA in each sample were
normalised using the housekeeping gene GAPDH as
described previously [15].
Statistical analysis
The Hardy–Weinberg equilibrium was tested separately in
cases and controls using a chi-square test. A threshold of P <
0.05 was used to indicate departure from Hardy–Weinberg
equilibrium. Association with susceptibility to RA was ana-
lysed by applying a chi-square test on 2 × 2 contingency
tables. The odds ratios were calculated with the 95% confi-
dence interval, and P  < 0.05 was considered significant.
Association with clinical features such as sex, age at onset, X-
ray damage (as defined by the modified Larsen score), RF sta-
tus and CCP status with each genotype were then analysed
using a chi-square test, the Kruskal–Wallis test or Cuzick's
trend test as appropriate. A cutoff value of 40 IU/ml and a cut-
off value of 5.5 U/ml were used as a criterion for RF and for
anti-CCP positivity, respectively. All analyses were carried out
using STATA statistical software (Release 9.1; STATA Corpo-
ration, College Station, TX, USA). Based on the strength of the
association described by Smyth and colleagues in T1D [14],
our study had a 73% power to detect a similar effect in RA.
Gene expression data were not normally distributed and the
differences were therefore compared using the Mann–Whit-
ney nonparametric tests. The interquartile range represents
the 25th and 75th percentiles of the distribution. All gene
expression analysis was performed using GraphPad Prism
Version 4 (GraphPad Software, San Diego, CA, USA).
Results
IFIH1 A946T is not associated with RA susceptibility or 
severity
Allele and genotype frequencies for IFIH1 A946T were in
Hardy–Weinberg equilibrium for both RA cases and controls.
The frequency of the 946C allele was 0.62 and 0.60 in the
patient group and in the control group, respectively (P = 0.3),
which was similar to that reported in the T1D study [14]. Gen-
otypes were not significantly different, indicating that this pol-
ymorphism is not a susceptibility gene for RA (Table 1). To
determine whether this marker influenced the disease pheno-
type, patients were stratified according to demographic and
clinical features. Allele frequencies and genotypes were not
significantly different after stratification by sex, age at onset,
presence of RF or presence of anti-CCP (Table 1). The modi-Available online http://arthritis-research.com/content/9/2/R40
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fied Larsen score was not significantly different in patients of
the three genotypes.
IFIH1 mRNA levels in peripheral blood mononuclear 
cells of RA patients and healthy controls
Levels of IFIH1, expressed as the ratio of IFIH1 mRNA copies
to those of GAPDH, were significantly higher in RA cases
(0.21 ± 0.5) than in healthy controls (0.10 ± 0.2) (P < 0.0001)
(Figure 1). We further investigated whether the IFIH1 A946T
genotype was associated with mRNA levels. The IFIH1 mRNA
levels in patients homozygous for the A allele (n = 63) and in
patients heterozygous for (n = 79) and homozygous for the G
allele (n = 29) were 0.20 ± 0.3, 0.23 ± 0.6 and 0.18 ± 0.3 (P
= 0.98), respectively. Similar results were observed in healthy
controls: IFIH1 mRNA levels were 0.10 ± 0.2, 0.11 ± 0.2 and
0.12 ± 0.1 (P = 0.7) for A homozygote controls (n = 76), for
heterozygous controls (n = 85) and for G homozygote con-
trols (n = 22), respectively.
Discussion
Our results indicate that the IFIH1 A946T SNP is not associ-
ated with susceptibility to RA. Although the present study
involved large populations it only had modest power (73%) to
detect an effect of the magnitude reported recently in T1D,
and therefore additional studies using large RA cohorts are
required to fully exclude an effect from IFIH1. Genetic suscep-
tibility to RA has been examined extensively; however, rela-
tively few studies have investigated the role of genetic factors
in RA severity. There is evidence of a significant impact on
radiological damage that is independent of covariates includ-
ing disease duration and RF status [16].
A recent study compared the variance in radiological hand
damage in monozygotic and dizygotic twins and pairs of unre-
lated RA patients. After assuming a linear relationship
between radiological progression and disease duration, the
variation in joint destruction was highest in unrelated pairs, fol-
lowed by dizygotic twins, and was smallest between monozy-
gotic twins supporting a genetic input [17]. We did not detect
Table 1
Genotype frequencies of the interferon induced with helicase domain 1 A946T polymorphism
Genotype frequency
GG AG AA
Rheumatoid arthritis
Patients 126 (13.7%) 446 (48.5%) 348 (37.8%)
Controls 144 (15.5%) 450 (48.4%) 335 (36.1%)
Odds ratio (95% confidence 
interval)
0.8 (0.6–1.1) 0.9 (0.8–1.2)
P value 0.2 0.6
Rheumatoid factor
Positive 76 (13.1%) 281 (48.5%) 222 (38.3%)
Negative 40 (15.2%) 126 (47.9%) 97 (36.9%)
Odds ratio (95% confidence 
interval)
0.8 (0.5–1.3) 1.0 (0.7–1.4)
P value 0.4 0.9
Cyclic citrullinated peptide
Positive 87 (13.1%) 328 (49.2%) 251 (37.7%)
Negative 31 (15.1%) 99 (48.3%) 75 (36.6%)
Odds ratio (95% confidence 
interval)
0.8 (0.5–1.4) 1.0 (0.7–1.4)
P value 0.5 1.0
Larsen score
Median 36.0 (13.4%) 27.5 (48.3%) 27.0 (38.3%)
P value 0.2
We assumed a multiplicative inheritance model by performing logistic regression. The model with the largest log-likelihood ratio was chosen as 
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a significant association of this marker with radiological dam-
age. Our results are consistent with linkage studies in RA that
have not found a genetic contribution for the region at 2q24.3
that encodes IFIH1 [18].
The genetic association of IFIH1 with T1D may be explained
by the reported link with preceding viral infections, as this
gene is thought to contribute to the apoptosis of virally
infected cells [19]. Viral RNA is sensed via a helicase domain
resulting in the activation of an N-terminal caspase recruitment
domain, which activates several key downstream pathways
including NF-κB and IRF3 [20]. The A946T SNP does not
reside in either the helicase or CARD domains, and therefore
the biological effects of this variant are unknown – although
the variant does lie in a region that is highly conserved
between mammals, suggesting functional importance. The
role of viruses in the pathogenesis of RA has been suggested,
and a polyarthritis resembling RA has been described after
infection with Epstein–Barr virus, parvovirus B19, HTLV-1 and
human herpes-6 or human herpes-8; however, evidence for a
role of viruses in RA is circumstantial and inconclusive [21].
Although no association between this genetic variant and RA
was detected, IFIH1 mRNA levels were greater in RA patients
compared with healthy controls. This gene is expressed at
high levels in immune such as CD4+ T cells, CD8+ T cells,
CD19+  B cells, monocytes and dendritic cells (USCS
Genome Browser–GNF expression Atlas, [22]) The upregula-
tion of IFIH1 in RA patients could be explained by the
increased expression of IFNβ because IFIH1 is a highly IFNβ-
inducible protein that is thought important in mediating IFNβ
effects such as growth inhibition and apoptosis [23]. Immuno-
histochemical analysis has shown IFNβ to be highly expressed
in rheumatoid synovium in fibroblast-like synoviocytes, den-
dritic cells and macrophages. Our finding of increased IFIH1
expression in peripheral blood leucocytes of patients suggests
that the increased levels of IFIH1 may result from overexpres-
sion of this immunomodulatory cytokine [24]. An alternative
explanation is that the increase is a reflection of a difference in
the cellular subpopulations in the peripheral blood of RA
patients and controls.
Conclusion
We conclude from the results of the present large case–con-
trol study that there is no significant role of the A946T IFIH1
polymorphism in the genetic susceptibility to RA or with the
development of more severe radiological damage. Levels of
IFIH1 mRNA were approximately twofold higher in peripheral
blood leucocytes of patients compared with controls, suggest-
ing upregulation in inflammatory cytokines such as IFNβ.
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